secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001370053-22-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023
--------------------------------------------------------------------------------

- Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.
- Cash & investments $590.5M as of Sep 30, 2022, down $24.7M from Dec 31, 2021.
- Collaboration revenue fell to $1.3M (Q3 2022) from $20.9M (Q3 2021) on no GSK milestones.
- Rosnilimab Phase 2 alopecia areata top-line data expected Q1 2023; ANB032 IND Q4 2022.
- Zejula royalty sale to DRI for up to $45M ($35M upfront); GSK earned $5M milestone for cobolimab Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/0001370053-22-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/anab-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001370053-22-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer